Related Experiment Video
Updated: Jun 12, 2026
10:44
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Development of tryptase inhibitors derived from thalidomide
Masashi Tetsuhashi1, Minoru Ishikawa, Mariko Hashimoto
1Institute of Molecular & Cellular Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan.
Bioorganic & Medicinal Chemistry
|June 22, 2010
Summary
Researchers developed novel tryptase inhibitors based on the thalidomide structure. A potent inhibitor, compound 7, demonstrated significant selectivity and efficacy with an IC50 of 78 nM.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pharmacology
Background:
- Tryptase is a serine protease implicated in allergic and inflammatory diseases.
- Existing tryptase inhibitors lack sufficient potency or selectivity.
- Thalidomide analogs offer a promising scaffold for drug development.
Purpose of the Study:
- To design and synthesize novel N-phenylphthalimide-based compounds as potential tryptase inhibitors.
- To investigate the structure-activity relationships (SAR) of these novel compounds.
- To identify a potent and selective tryptase inhibitor for further development.
Main Methods:
- Synthesis of a series of N-phenylphthalimide derivatives.
- Structure-activity relationship (SAR) analysis based on inhibitory activity against tryptase.
- Enzyme inhibition assays to determine IC50 values.
Main Results:
- Successful development of a novel series of tryptase inhibitors.
- Identification of compound 7, 2-(4-cyanophenyl)isoindole-1,3-dione-5-yl 3-(2-aminopyridin-5-yl)propanoate, as a lead candidate.
- Compound 7 exhibited potent and selective tryptase inhibition with an IC50 value of 78 nM.
Conclusions:
- The N-phenylphthalimide scaffold is effective for developing potent tryptase inhibitors.
- Compound 7 represents a promising therapeutic candidate for tryptase-mediated conditions.
- Further preclinical evaluation of compound 7 is warranted.
Related Concept Videos
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:07Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:30Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
01:15Drugs that Stabilize Microtubules
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...